Heide Siggelkow, MD

Professor of Internal Medicine/Endocrinology

Assistant Professor (C2, suspended)
Department of Gastroenterology and Endocrinology

Date of birth
May 28, 1962, Solingen/ Germany

Universitätsmedizin Göttingen
Abt. für Gastroenterologie und Endokrinologie
Robert-Koch-Str. 40, 37075 Göttingen
phone: +49 (0) 551/39-6326/Fax: +49 (0) 551/39-6921
e-mail: Opens window for sending emailhsiggel(at)med.uni-goettingen.de
Website: Opens external link in new windowwww.gastroenterologie.med.uni-goettingen.de

Academic appointments

1986–1991 MD thesis at the Tufts University, Boston, USA, Max-Planck-Institute for Experimental Endocrinology and the University of Hannover ("summa cum laude")
1989–1990 ÄIP in General Surgery, Gehrden, University of Hannover
1991–1994 Dep. of Gastroenterology und Endocrinology, University of Göttingen (Prof. W. Creutzfeldt, Prof. G. Ramadori), Section of Endocrinology (Prof. M. Hüfner) until 12/05 (A13/C2)
1994–1995 Dep. of Nuclear Medicine (Prof. Dr. med. D. Emrich and Prof. Dr. med. W. Becker)
1995– Dep. of Gastroenterology und Endocrinology, University of Göttingen (Prof. G. Ramadori), Section of Endocrinology (Prof. M. Hüfner) until 12/05 (A13/C2)
1998Specialization in Internal Medicine
2000Venia legendi for Internal Medicine
2001Specialization in Endocrinology
2005Specialization in Diabetology DDG
2005Specialization in Osteology DVO
2006 Clinical Endocrinology in Private Practice (ENDOKRINOLOGICUM Göttingen)
Assistant Professor in the Department of Gastroenterology and Endocrinology at the University Medicine, Goettingen (C2 suspended, 13 h)
2009 Professor for Internal Medicine (apl)

Other professional activities

Reviewer activity

Experimental and Clinical Endocrinology and Diabetes, Hormone and Metabolic Research, Molecular and Cellular Endocrinology, Journal of Cellular Biochemistry, European Journal of Pharmacology, Maturitas, Osteology

Congress President Osteology 2003 in Goettingen (Congress of the Dachverband der deutschsprachigen osteologischen Fachgesellschaften aus Deutschland, Österreich und der Schweiz [DVO])
2002– Mentor in the Mentoring Program of the University Medicine of Goettingen
2011– President of the Association of german-language societies in the special field of osteology


Since 1991

American Society of Bone and Mineral Research (ASBMR)

Since 1991 Bund Deutscher Internisten (BDI)
Since 1992

German Society of Endocrinology (DGE)

Since 1994

German Society of Osteology (DGO, Board member since 2007)

Since 1995

German Society of Diabetes (DDG)

Since 1995

European Calcified Tissue Society (ECTS)

Since 2007

Bund der Osteologen Niedersachsens (BDO)

Since 2008

representative of DGO in Dachverband der deutschsprachigen osteologischen Fachgesellschaften aus Deutschland, Österreich und der Schweiz (DVO)

Selected recent publications:

Siggelkow H, Rebenstorff K, Kurre W et al. Development of the osteoblast phenotype in primary human osteoblasts during time in culture. J Cell Biochem 1999; 75 (1): 22–35. (IF: 2.8)

Viereck V, Grundker C, Blaschke S, Niederkleine B, Siggelkow H et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 2003; 88 (9): 4206–4213. (IF: 5.9)

Siggelkow H, Eidner T, Lehmann G et al. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Miner Res 2003; 18 (3): 529–538. (IF: 6.2)

Siggelkow H, Schmidt E, Hennies B, Hüfner M. Matrix Extracellular Phosphoglycoprotein (MEPE) shows differentiation dependent expression in human models of osteoblast differentiation. Bone 2004; 35 (2): 570–576. (IF: 3.6)

Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006; 103 (42): 15558–15563. (IF: 10.2)

Viereck V, Siggelkow H, Pannem R et al. Alteration of the insulin-like growth factor axis during in vitro differentiation of the human osteosarcoma cell line HOS 58. J Cell Biochem 2007; 102 (1): 28–40.

Ponce ML, Koelling S, Kluever A, Heinemann DE, Miosge N, Wulf G, Frosch KH, Schütze N, Hufner M, Siggelkow H. Coexpression of osteogenic and adipogenic differentiation markers in selected subpopulations of primary human mesenchymal progenitor cells. J Cell Biochem 2008; 104 (4): 1342-1355. (IF: 2.7)

Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, Toledo SP, Toledo RA, Tavares MR, Alevizaki M, Mian C, Siggelkow H et al.; and for the International RET Exon 10 Consortium. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat 2010 Oct 26. [Epub ahead of print] (IF:6.4)

Siggelkow H, Etmanski M, Bozkurt S et al. Genetic polymorphisms in 11ß-hydroxysteroid dehydrogenase HSD11B1 influence post dexamethasone cortisol levels as possible pathogenetic factor of bone mineral density in aging bone and osteoporosis. [Submitted to JCEM 2012, in review]